in vivo News and Research

RSS

Scientists re-produce the human body's own cancer-killing cells through gene therapy

New hope to cancer sufferers comes from research by South Korean scientists who have found a way to re- produce the human body's own cancer-killing cells through gene therapy.

1 Mar 2005

New medical devices can cause new immune problems

Medical devices are traditionally thought of as fairly simple implants such as stents and hip replacements – pieces of plastic or metal that are placed in the body to handle a very specific function. But biomedical devices now on the drawing board are considerably more sophisticated and represent an unprecedented melding of man and machine.

28 Feb 2005

Better ways to heal and regenerate bones using microcomputed tomography imaging

Tissue engineers can choose from a wide range of living cells, biomaterials and proteins to repair a bone defect. But finding the optimum combination requires improved methods for tracking the healing process.

20 Feb 2005

Programmed cell death may provide clues to cancer and autoimmune diseases therapies

Dartmouth Medical School geneticists have found links in the cell death machinery of worms and mammals, opening new avenues for studying and targeting a process vital to development and implicated in cancer and autoimmune diseases.

16 Feb 2005

Renovis announces investigational medicine for multiple sclerosis study

Renovis announced today the initiation of a Phase Ia clinical trial for REN-850, an investigational oral small molecule that is being targeted for the treatment of multiple sclerosis (MS).

14 Feb 2005

Inserting corrective genes into the brain to fight Parkinson's disease

An international team of scientists has used gene therapy in two separate studies to renew brain cells and restore normal movements in monkeys and rats with a drug-induced form of Parkinson's disease.

8 Feb 2005

Nano-sized particles enable researchers to visualize a tumor using only infrared light

Nano-sized particles embedded with bright, light-emitting molecules have enabled researchers to visualize a tumor more than one centimeter below the skin surface using only infrared light.

7 Feb 2005

New way to assess the potentially damaging effects of prenatal drug exposure

Scientists have demonstrated a new way to assess the potentially damaging effects of prenatal drug exposure--a technique that could also be used to monitor a fetus's response to therapeutic drugs--using sophisticated, noninvasive medical imaging tools.

7 Feb 2005

New insight into how tumor cells can become resistant to anti-cancer therapy

The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically “jump” or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro.

18 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Adenosine Therapeutics awarded grant to develop drug eluting stents to prevent restenosis

Adenosine Therapeutics announced today the award of a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health.

6 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Smoking habits during pregnancy may cause genetic instability in the foetus

The Spanish Pediatrics Association has recently awarded the Pediatrics laboratory at the University of Navarre for a research into tobacco and foetal genetic instability.

2 Dec 2004

Novel anti-obesity compound shows promise for treatment of obesity

Arena Pharmaceuticals announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity.

30 Nov 2004

Astronaut's eyes may become windows on the bloodstream

Our eyes may become more than windows of the soul if a multidisciplinary team of University of Michigan researchers succeeds with a clever combination of nanoparticles and ultrafast pulsed laser to see individual cells as they zip past in the bloodstream.

29 Nov 2004

Study links a novel protein pathway to the aggressive progression of breast cancer

Cytogen Corporation today announced the publication of a study linking a novel protein pathway to the aggressive progression of breast cancer.

24 Nov 2004

Acetaminophen shows positive cardioprotective effects In heart attack, arrhythmia

Long an under-studied yet widely-used over-the-counter medication, acetaminophen over the last few years is becoming recognized for a range of potential therapeutic uses beyond headache and pain.

16 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004